ENLV
Enlivex Ltd.
Price Chart
Latest Quote
$0.62
+0.00 (+0.60%)
Current Price
| Previous Close | $0.62 |
| Open | $0.64 |
| Day High | $0.65 |
| Day Low | $0.61 |
| Volume | 323,676 |
Stock Information
| Shares Outstanding | 241.05M |
| Total Debt | $641K |
| Cash Equivalents | $5.75M |
| Net Income | $1.24B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $149.86M |
| P/E Ratio | 0.02 |
| EPS (TTM) | $25.55 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $142.47M |
| Income | $1.24B |
| Book/sh | $8.15 |
| Cash/sh | $0.02 |
| Employees | 34 |
Financial Ratios
| Quick Ratio | 0.69 |
| Current Ratio | 193.24 |
| Debt/Eq | 0.03 |
Returns & Margins
| ROA | -0.80% |
| ROE | 126.17% |
Ownership
| Insider Ownership | 85.26% |
| Institutional Ownership | 1.51% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.80 |
| P/B | 0.08 |
Analyst Data
| Recommendation | none |
| Target Price | $20.00 |
Technical Indicators
| SMA20 | $0.73 |
| SMA50 | $0.78 |
| SMA200 | $0.96 |
| RSI | 26.62 |
| ATR | 0.0660 |
| Shares Float | 57.72M |
| Short Float | 0.17% |
| Short Ratio | 1.19 |
| Volatility | 1.47 |
| Rel Volume | 0.72 |
Performance History
| Week | -13.49% |
| Month | -11.77% |
| Quarter | -42.41% |
| 6 Months | -26.48% |
| YTD | -17.62% |
| Year | -39.61% |
| 3 Years | -76.88% |
| 5 Years | -93.49% |
| 10 Years | -99.15% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.62 | 323,700 |
| 2026-06-17 | $0.62 | 267,400 |
| 2026-06-16 | $0.63 | 310,500 |
| 2026-06-15 | $0.66 | 306,100 |
| 2026-06-12 | $0.67 | 178,500 |
| 2026-06-11 | $0.72 | 184,400 |
| 2026-06-10 | $0.67 | 296,400 |
| 2026-06-09 | $0.69 | 355,500 |
| 2026-06-08 | $0.71 | 114,000 |
| 2026-06-05 | $0.71 | 307,700 |
| 2026-06-04 | $0.79 | 384,400 |
| 2026-06-03 | $0.85 | 490,500 |
| 2026-06-02 | $0.85 | 701,700 |
| 2026-06-01 | $0.86 | 813,200 |
| 2026-05-29 | $0.81 | 753,500 |
| 2026-05-28 | $0.76 | 1,093,700 |
| 2026-05-27 | $0.78 | 1,326,400 |
| 2026-05-26 | $0.68 | 593,700 |
| 2026-05-22 | $0.72 | 112,000 |
| 2026-05-21 | $0.72 | 126,900 |
| 2026-05-20 | $0.70 | 134,600 |
| 2026-05-19 | $0.70 | 97,500 |
About Enlivex Ltd.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
đ° Latest News
Enlivex advances Allocetra while expanding into prediction markets
Proactive âĸ 2026-05-11T17:39:35Z
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook
Insider Monkey âĸ 2026-04-21T02:46:33Z
Enlivex Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-25T14:18:15Z
Enlivex Therapeutics announces new listing of RAIN token on Kraken
TipRanks âĸ 2026-02-11T13:11:38Z
Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market
DLNews âĸ 2025-11-25T17:14:38Z
Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120%
Coinspeaker âĸ 2025-11-24T21:51:47Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-11-24T15:30:19ZEXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play
Benzinga âĸ 2025-11-24T14:46:42Z
Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy
CoinDesk âĸ 2025-11-24T13:00:00Z
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Simply Wall St. âĸ 2025-09-14T14:02:13Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $15,000,000 | $14,931,000 | $25,151,000 | $25,797,000 |
| Other Income Expense | $1,632,395,000 | $-1,139,000 | $-5,468,000 | $-6,084,000 |
| Net Non Operating Interest Income Expense | $779,000 | $1,056,000 | $1,551,000 | $821,000 |
| Total Other Finance Cost | $13,000 | $13,000 | $14,000 | $14,000 |
| Operating Expense | $15,000,000 | $14,931,000 | $25,151,000 | $25,797,000 |
| Other Operating Expenses | $111,000 | $105,000 | $906,000 | $402,000 |
| General And Administrative Expense | $5,685,000 | $4,808,000 | $5,233,000 | $6,702,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Net Interest Income | $779,000 | $1,056,000 | $1,551,000 | $821,000 |
| Interest Income | $792,000 | $1,069,000 | $1,565,000 | $835,000 |
| Normalized Income | $-10,805,582 | $-13,875,000 | $-23,600,000 | $-24,976,000 |
| Net Income From Continuing And Discontinued Operation | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Total Operating Income As Reported | $-15,029,000 | $-15,888,000 | $-29,395,000 | $-25,797,000 |
| Net Income Common Stockholders | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Net Income | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Net Income Including Noncontrolling Interests | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Net Income Continuous Operations | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Pretax Income | $1,618,174,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Special Income Charges | $-29,000 | $-957,000 | $-4,244,000 | $0 |
| Interest Income Non Operating | $792,000 | $1,069,000 | $1,565,000 | $835,000 |
| Operating Income | $-15,000,000 | $-14,931,000 | $-25,151,000 | $-25,797,000 |
| Per Share | ||||
| Diluted EPS | - | $-0.73 | $-1.56 | $-1.69 |
| Basic EPS | - | $-0.73 | $-1.56 | $-1.69 |
| Other | ||||
| Tax Effect Of Unusual Items | $386,061,418 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,647,063,000 | $-13,247,000 | $-18,848,000 | $-18,936,000 |
| Total Unusual Items | $1,632,395,000 | $-1,139,000 | $-5,468,000 | $-6,084,000 |
| Total Unusual Items Excluding Goodwill | $1,632,395,000 | $-1,139,000 | $-5,468,000 | $-6,084,000 |
| Reconciled Depreciation | $332,000 | $545,000 | $835,000 | $777,000 |
| EBITDA (Bullshit earnings) | $-14,668,000 | $-14,386,000 | $-24,316,000 | $-25,020,000 |
| EBIT | $-15,000,000 | $-14,931,000 | $-25,151,000 | $-25,797,000 |
| Diluted NI Availto Com Stockholders | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Tax Provision | $382,646,000 | $0 | $0 | - |
| Gain On Sale Of Ppe | $-29,000 | $-957,000 | $-4,244,000 | $0 |
| Gain On Sale Of Security | $1,632,424,000 | $-182,000 | $-1,224,000 | $-6,084,000 |
| Other Taxes | $0 | $-605,000 | $0 | $0 |
| Research And Development | $9,204,000 | $10,623,000 | $19,012,000 | $18,693,000 |
| Selling General And Administration | $5,685,000 | $4,808,000 | $5,233,000 | $6,702,000 |
| Other Gand A | $1,830,000 | $1,261,000 | $1,440,000 | $2,001,000 |
| Insurance And Claims | $281,000 | $351,000 | $567,000 | $895,000 |
| Salaries And Wages | $3,574,000 | $3,196,000 | $3,226,000 | $3,806,000 |
| Diluted Average Shares | - | $20,513,992 | $18,574,484 | $18,394,886 |
| Basic Average Shares | - | $20,513,992 | $18,574,484 | $18,394,886 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,934,948,000 | $23,589,000 | $30,084,000 | $56,841,000 |
| Total Assets | $2,326,998,000 | $27,687,000 | $36,831,000 | $67,642,000 |
| Total Non Current Assets | $583,820,000 | $1,694,000 | $3,067,000 | $15,312,000 |
| Other Non Current Assets | $582,874,000 | $317,000 | $300,000 | $299,000 |
| Non Current Prepaid Assets | $8,000 | $18,000 | $187,000 | $113,000 |
| Current Assets | $1,743,178,000 | $25,993,000 | $33,764,000 | $52,330,000 |
| Other Current Assets | $24,273,000 | - | - | - |
| Hedging Assets Current | $1,708,789,000 | $0 | - | - |
| Assets Held For Sale Current | $0 | $198,000 | $5,108,000 | $0 |
| Prepaid Assets | $3,851,000 | $884,000 | $1,107,000 | $1,439,000 |
| Receivables | $510,000 | $1,415,000 | $229,000 | $647,000 |
| Other Receivables | $348,000 | $1,347,000 | $113,000 | $125,000 |
| Taxes Receivable | $162,000 | $68,000 | $116,000 | $522,000 |
| Cash Cash Equivalents And Short Term Investments | $5,755,000 | $23,496,000 | $27,320,000 | $50,244,000 |
| Cash And Cash Equivalents | $1,894,000 | $3,301,000 | $813,000 | $49,945,000 |
| Cash Equivalents | $314,000 | $1,044,000 | $0 | $47,822,000 |
| Cash Financial | $1,580,000 | $2,257,000 | $813,000 | $2,123,000 |
| Non Current Accounts Receivable | - | $206,000 | - | - |
| Restricted Cash | - | - | - | $113,000 |
| Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $641,000 | $534,000 | $1,032,000 | $4,847,000 |
| Long Term Debt And Capital Lease Obligation | $383,000 | $299,000 | $686,000 | $4,194,000 |
| Current Debt And Capital Lease Obligation | $258,000 | $235,000 | $346,000 | $653,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $392,050,000 | $4,098,000 | $6,747,000 | $10,801,000 |
| Total Non Current Liabilities Net Minority Interest | $383,029,000 | $299,000 | $686,000 | $4,194,000 |
| Non Current Deferred Liabilities | $382,646,000 | $0 | - | - |
| Non Current Deferred Taxes Liabilities | $382,646,000 | $0 | - | - |
| Current Liabilities | $9,021,000 | $3,799,000 | $6,061,000 | $6,607,000 |
| Payables And Accrued Expenses | $6,035,000 | $2,015,000 | $3,593,000 | $5,195,000 |
| Payables | $3,808,000 | $811,000 | $827,000 | $1,948,000 |
| Accounts Payable | $3,808,000 | $811,000 | $827,000 | $1,948,000 |
| Other Current Liabilities | - | $142,000 | $1,233,000 | - |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $1,934,948,000 | $23,589,000 | $30,084,000 | $56,841,000 |
| Total Equity Gross Minority Interest | $1,934,948,000 | $23,589,000 | $30,084,000 | $56,841,000 |
| Stockholders Equity | $1,934,948,000 | $23,589,000 | $30,084,000 | $56,841,000 |
| Gains Losses Not Affecting Retained Earnings | $1,101,000 | $1,101,000 | $1,101,000 | $1,101,000 |
| Other Equity Adjustments | $1,101,000 | $1,101,000 | $1,101,000 | - |
| Retained Earnings | $1,108,421,000 | $-127,107,000 | $-112,093,000 | $-83,025,000 |
| Other | ||||
| Ordinary Shares Number | $237,381,498 | $23,650,989 | $18,598,555 | $18,421,852 |
| Share Issued | $237,381,498 | $23,650,989 | $18,598,555 | $18,421,852 |
| Tangible Book Value | $1,934,948,000 | $23,589,000 | $30,084,000 | $56,841,000 |
| Invested Capital | $1,934,948,000 | $23,589,000 | $30,084,000 | $56,841,000 |
| Working Capital | $1,734,157,000 | $22,194,000 | $27,703,000 | $45,723,000 |
| Capital Lease Obligations | $641,000 | $534,000 | $1,032,000 | $4,847,000 |
| Total Capitalization | $1,934,948,000 | $23,589,000 | $30,084,000 | $56,841,000 |
| Additional Paid In Capital | $796,696,000 | $146,910,000 | $138,939,000 | $136,648,000 |
| Capital Stock | $28,730,000 | $2,685,000 | $2,137,000 | $2,117,000 |
| Common Stock | $28,730,000 | $2,685,000 | $2,137,000 | $2,117,000 |
| Long Term Capital Lease Obligation | $383,000 | $299,000 | $686,000 | $4,194,000 |
| Current Capital Lease Obligation | $258,000 | $235,000 | $346,000 | $653,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,728,000 | $1,407,000 | $889,000 | $759,000 |
| Current Accrued Expenses | $2,227,000 | $1,204,000 | $2,766,000 | $3,247,000 |
| Net PPE | $938,000 | $1,153,000 | $2,580,000 | $14,900,000 |
| Accumulated Depreciation | $-3,838,000 | $-3,650,000 | $-3,990,000 | $-3,527,000 |
| Gross PPE | $4,776,000 | $4,803,000 | $6,570,000 | $18,427,000 |
| Leases | $947,000 | $947,000 | $1,431,000 | $8,606,000 |
| Other Properties | $3,180,000 | $3,270,000 | $4,548,000 | $9,296,000 |
| Machinery Furniture Equipment | $649,000 | $586,000 | $591,000 | $525,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $3,861,000 | $20,195,000 | $26,507,000 | $299,000 |
| Foreign Currency Translation Adjustments | - | - | $1,101,000 | $1,101,000 |
| Dueto Related Parties Current | - | - | - | - |
| Investments And Advances | - | - | - | - |
| Other Investments | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,484,000 | $-13,111,000 | $-23,759,000 | $-32,075,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,416,000 | $-13,008,000 | $-23,523,000 | $-23,953,000 |
| Cash Flow From Continuing Operating Activities | $-10,416,000 | $-13,008,000 | $-23,523,000 | $-23,953,000 |
| Operating Gains Losses | $-508,000 | $317,000 | $3,881,000 | $1,983,000 |
| Investing Activities | ||||
| Capital Expenditure | $-68,000 | $-103,000 | $-236,000 | $-8,122,000 |
| Investing Cash Flow | $-1,323,000 | $9,059,000 | $-25,968,000 | $62,524,000 |
| Cash Flow From Continuing Investing Activities | $-1,323,000 | $9,059,000 | $-25,968,000 | $62,524,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,381,000 | $6,452,000 | $360,000 | $0 |
| Financing Cash Flow | $10,381,000 | $6,454,000 | $360,000 | $150,000 |
| Cash Flow From Continuing Financing Activities | $10,381,000 | $6,454,000 | $360,000 | $150,000 |
| Net Common Stock Issuance | $10,381,000 | $6,452,000 | $360,000 | $0 |
| Common Stock Issuance | $10,381,000 | $6,452,000 | $360,000 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $2,373,000 | $3,731,000 | $1,226,000 | $50,357,000 |
| Beginning Cash Position | $3,731,000 | $1,226,000 | $50,357,000 | $11,636,000 |
| Changes In Cash | $-1,358,000 | $2,505,000 | $-49,131,000 | $38,721,000 |
| Proceeds From Stock Option Exercised | $0 | $2,000 | $0 | $150,000 |
| Net Investment Purchase And Sale | $-1,256,000 | $8,978,000 | $-25,865,000 | $70,646,000 |
| Sale Of Investment | $42,741,000 | $41,348,000 | $301,000 | $72,553,000 |
| Purchase Of Investment | $-43,997,000 | $-32,370,000 | $-26,166,000 | $-1,907,000 |
| Net PPE Purchase And Sale | $-67,000 | $81,000 | $-103,000 | $-8,122,000 |
| Sale Of PPE | $1,000 | $184,000 | $133,000 | $0 |
| Purchase Of PPE | $-68,000 | $-103,000 | $-236,000 | $-8,122,000 |
| Change In Working Capital | $815,000 | $-1,218,000 | $-1,818,000 | $804,000 |
| Change In Other Current Liabilities | $-206,000 | $-591,000 | $-955,000 | $-1,326,000 |
| Change In Payables And Accrued Expense | $4,072,000 | $-1,060,000 | $-1,471,000 | $1,852,000 |
| Change In Accrued Expense | $1,075,000 | $-1,044,000 | $-350,000 | $684,000 |
| Change In Payable | $2,997,000 | $-16,000 | $-1,121,000 | $1,168,000 |
| Change In Account Payable | $2,997,000 | $-16,000 | $-1,121,000 | $1,168,000 |
| Change In Prepaid Assets | $-3,051,000 | $433,000 | $608,000 | $278,000 |
| Other Non Cash Items | $263,000 | $297,000 | $696,000 | $831,000 |
| Stock Based Compensation | $1,783,000 | $2,065,000 | $1,951,000 | $2,712,000 |
| Unrealized Gain Loss On Investment Securities | $-1,631,275,000 | $0 | $0 | - |
| Deferred Tax | $382,646,000 | $0 | $0 | - |
| Deferred Income Tax | $382,646,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $332,000 | $545,000 | $835,000 | $777,000 |
| Depreciation And Amortization | $332,000 | $545,000 | $835,000 | $777,000 |
| Depreciation | $332,000 | $545,000 | $835,000 | $777,000 |
| Gain Loss On Investment Securities | $-536,000 | $-558,000 | $-343,000 | $1,983,000 |
| Gain Loss On Sale Of PPE | $-1,000 | $-82,000 | $-20,000 | - |
| Net Income From Continuing Operations | $1,235,528,000 | $-15,014,000 | $-29,068,000 | $-31,060,000 |
| Effect Of Exchange Rate Changes | - | - | $0 | $0 |
| Pension And Employee Benefit Expense | - | - | - | - |
Fetched: 2026-06-19